C12Y 304/24068
Tentoxilysin , i.e. tetanus neurotoxin
Official title: Tentoxilysin (3.4.24.68), i.e. tetanus neurotoxin
C12Y304/24068 (Tentoxilysin , i.e. tetanus neurotoxin) appears on 13 US grants and 29 published applications in this corpus.
Search patents in C12Y- Granted patents
- 13
- Published applications
- 29
- Assignees
- 17
- Inventors
- 60
- Latest grant
- 4 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 1 |
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 1 |
| 2007 | 0 | 0 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 1 | 0 |
| 2011 | 0 | 2 |
| 2012 | 0 | 0 |
| 2013 | 1 | 0 |
| 2014 | 1 | 2 |
| 2015 | 0 | 2 |
| 2016 | 1 | 2 |
| 2017 | 1 | 3 |
| 2018 | 1 | 2 |
| 2019 | 0 | 3 |
| 2020 | 1 | 1 |
| 2021 | 2 | 2 |
| 2022 | 2 | 1 |
| 2023 | 0 | 2 |
| 2024 | 0 | 2 |
| 2025 | 1 | 1 |
| 2026 | 1 | 1 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Pegylated tetanus neurotoxins and treatment of hypotonia4 Aug 2026US 12,697,379 B2Snoretox Pty Ltd
- Cell-free expression system having novel inorganic polyphosphate-based energy regeneration18 Feb 2025US 12,227,778 B2Nature's Toolbox, Inc.
- Recombinant clostridial neurotoxins with increased duration of effect14 Jun 2022US 11,357,821 B2MERZ PHARMA GmbH & CO. KGaA
- Fusion proteins comprising a non-cytotoxic protease, a translocation domain, and a targeting moiety that binds a galanin receptor and methods for treating, preventing or ameliorating pain using such fusion proteins15 Feb 2022US 11,248,219 B2Allergan, Inc.
- Methods for purifying clostridial neurotoxin20 Jul 2021US 11,066,451 B2Ipsen Biopharm Ltd.
- Clostridial Neurotoxins Comprising an Activating Endosomal Protease Cleavage Site20 Aug 2026US 2026/0242764 A1
- Method for purifying tetanus toxin or variants thereof18 Sep 2025US 2025/0290058 A1Shanghai Microdom Biotech Co., Ltd
- Preparation method for modified toxin polypeptide11 Jul 2024US 2024/0228533 A9Chongqing Claruvis Pharmaceutical Co., Ltd.
- Preparation method for modified toxin polypeptide25 Apr 2024US 2024/0132540 A1Chongqing Claruvis Pharmaceutical Co., Ltd.
- A disintegrin and metalloproteinase with a thrombospondin type i motif, member 13 (adamts-13) mutants, compositions and therapeutic methods thereof21 Sep 2023US 2023/0295597 A1Hadasit Medical Research Services and Development Ltd.
Most cited
By later US patents
- High level expression of recombinant toxin proteins12US 8,530,171 B2Pfenex Inc. · 2013
- Cell membrane translocation of regulated snare inhibitors, compositions therefor, and methods for treatment of disease5US 9,504,735 B22016
- Purification of polysaccharide protein conjugates5US 9,782,468 B2Shantha Biotechnics Private Limited · 2017
- Materials and methods relating to immune responses to fusion proteins4US 7,816,334 B2Cancer Research Technology Limited · 2010
- Cationic neurotoxins4US 9,920,310 B2Ipsen Bioinnovation Limited · 2018